Scleroderma, Systemic
79
11
14
48
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
18 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.6%
6 terminated out of 79 trials
88.9%
+2.3% vs benchmark
10%
8 trials in Phase 3/4
38%
18 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 48 completed trials
Clinical Trials (79)
Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism
Efficacy and Safety of Imatinib in Scleroderma
Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis
Trichoscopy and Systemic Scleroderma
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
Western Sweden Systemic Sclerosis Project
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.
Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
Periodontal Microbiota in Systemic Sclerosis
A Study of Guselkumab in Participants With Systemic Sclerosis
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
Making it Work Program for Systemic Sclerosis